ChebliMradMD

Hematology Oncology Staff Physician

Dr. Mrad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University at BuffaloFellowship, Hematology and Medical Oncology, 2018 - 2021
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2015 - 2018
Lebanese University School of MedicineClass of 2013

PubMed

226 citations
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Joshua K. Sabari, Giulia Costanza Leonardi, Catherine A. Shu, Renato Umeton, Joseph Montecalvo
Annals of Oncology. 2018-10-01
4 citations
Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States.
Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber
Scientific Reports. 2021-12-02
39 citations
The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers.
Joshua K. Sabari, Fernando C. Santini, Alison M. Schram, Isabella Bergagnini, Ruqin Chen
Oncotargets and Therapy. 2017-04-06

Journal Articles

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology